Company Focuses on Growing Medical
Transportation and Payer & Provider Businesses, Navigates
Municipal Uncertainty and Migrant Services Transition
Management to Host Conference Call and Webcast
Today at 5:00 PM Eastern Time
DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading
provider of technology-enabled mobile health and medical
transportation services, today announced financial and operating
results for the quarter ended March 31, 2025.
Lee Bienstock, Chief Executive Officer of DocGo, commented, “The
impact of ongoing policy changes in Washington and adjustments to
public spending on healthcare-related projects have created
substantial uncertainty in our Government Population Health
vertical at the federal, state and local levels. As a result, we
have decided to remove all non-migrant Government Population Health
revenue — and any related projections — from our 2025 guidance. I
want to be clear, this revision is driven by our Government
Population Health vertical. Our Hospital and Payer & Provider
verticals continue to perform in line with expectations and we
believe they are on a solid growth trajectory. During the quarter
we completed a record number of medical transports along with
several new contract wins and are experiencing care gap closure
visit volumes that are approaching three times the amount we did
this time last year.” Bienstock concluded, “We believe our medical
transportation and mobile health businesses hold tremendous promise
and value for our company and for the healthcare system at large,
and we look forward to their continued growth.”
2025 Guidance
- Full-year 2025 revenue is expected to be $300-$330 million,
compared to the previous estimate of $410-$450 million, due to the
Company’s decision to remove any non-migrant municipal population
health revenue from its 2025 guidance. Revenue expectations from
the Company’s Medical Transportation and Payer & Provider
businesses and remaining migrant services healthcare work are
unchanged.
- Full-year 2025 adjusted EBITDA1 is now expected to be a loss of
$20-$30 million, compared to the previous expectation of a 5%
adjusted EBITDA margin.1
Norm Rosenberg, Chief Financial Officer of DocGo, also
commented, “We plan to aggressively cut SG&A over the next
several quarters, and anticipate positive cash flow through the
balance of the year driven by collections of our outstanding
migrant-related receivables. Additionally, we plan to utilize our
strong balance sheet to take advantage of opportunities being
presented by the current market uncertainty to grow both
organically and through M&A.”
First Quarter 2025 Financial Highlights
- Total revenue for the first quarter of 2025 was $96.0 million,
compared to $192.1 million in the first quarter of 2024. The
decline was due primarily to the planned wind-down of
migrant-related programs.
- GAAP gross margin (which includes depreciation and amortization
expenses of $3.8 million) for the first quarter of 2025 was 28.2%,
compared to 32.8% in the first quarter of 2024.
- Adjusted gross margin2 for the first quarter of 2025 was 32.1%,
compared to 35.0% in the first quarter of 2024.
- Net loss for the first quarter of 2025 was $11.1 million,
compared to net income of $10.6 million in the first quarter of
2024.
- Adjusted EBITDA2 loss was $3.9 million for the first quarter of
2025, compared to adjusted EBITDA of $24.1 million for the first
quarter of 2024.
- Mobile Health Services revenue for the first quarter of 2025
was $45.2 million, compared to $143.9 million for the first quarter
of 2024. The decline was due primarily to the wind-down of
migrant-related programs.
- Transportation Services revenue in the first quarter of 2025
was $50.8 million, compared to $48.2 million for the first quarter
of 2024.
- As of March 31, 2025, the Company held total cash and cash
equivalents, including restricted cash, of approximately $103.1
million, compared to $107.3 million as of December 31, 2024.
- During the first quarter of 2025, the Company repurchased 1.95
million shares of common stock for a total cost of approximately
$5.8 million.
- During the first quarter of 2025 the Company generated $9.7
million of cash flow from operations compared to cash used in
operations of $10.6 million in the first quarter of 2024.
Select Corporate Highlights for the First Quarter of 2025 and
Recent Weeks
- Signed a contract with a major New York health plan to offer
DocGo Primary Care services to members who prefer the convenience
of receiving healthcare in their home.
- Surpassed 900,000 patients assigned by the Company’s payer and
provider partners for care gap closure services.
- Signed a two-year contract with the North Texas division of a
national health system to provide medical transportation services
for their network of hospitals in Dallas and Fort Worth, TX.
- Experienced a record quarter for the Company’s medical
transportation segment in terms of revenue and trip volume.
- Signed a one-year contract that expands the Company’s
relationship with a California-based cardiology group and extends
the Company’s offering beyond CIED to provide virtual care
management services for an additional 1,000 of their patients.
- Continued enhancing the Company's tech stack with features that
aim to improve transportation turnaround times and enable a 40%
improvement in address search functionality for platform user
requests.
- Adjusted EBITDA and adjusted EBITDA margin are non-GAAP
financial measures. We have not reconciled adjusted EBITDA or
adjusted EBITDA margin outlook to the most comparable GAAP outlooks
because it is not possible to do so without unreasonable efforts
due to the uncertainty and potential variability of reconciling
items, which are dependent on future events and often outside of
management’s control and which could be significant. Because such
items cannot be reasonably predicted with the level of precision
required, we are unable to provide outlooks for the comparable GAAP
measures (net income and net margin). Forward-looking estimates of
adjusted EBITDA and adjusted EBITDA margin are made in a manner
consistent with the relevant definitions and assumptions noted
herein.
- Adjusted gross margin and adjusted EBITDA are non-GAAP
financial measures. See “Non-GAAP Financial Measures” below for
additional information on these non-GAAP financial measures and
reconciliations to the most comparable GAAP measures.
Conference Call and Webcast Details
Thursday, May 8th, 2025 at 5:00 PM
ET
1-800-717-1738 - Investors Dial
1-646-307-1865 - Int’l Investors Dial
Conference ID: 65854
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1714626&tp_key=4f3bf2b60e
The webcast can also be accessed under Events on the Investors
section of the Company’s website, https://ir.docgo.com/.
About DocGo
DocGo is leading the proactive healthcare revolution with an
innovative care delivery platform that includes mobile health
services, remote patient monitoring and ambulance services. DocGo
is helping to reshape the traditional four-wall healthcare system
by providing high quality, highly accessible care to patients where
and when they need it. DocGo’s proprietary technology and
relationships with a dedicated field staff of certified health
professionals elevate the quality of patient care and drive
business efficiencies for municipalities, hospital networks and
health insurance providers. With Mobile Health, DocGo empowers the
full promise and potential of telehealth by facilitating healthcare
treatment, in tandem with a remote advanced practice provider, in
the comfort of a patient’s home or workplace. Together with DocGo’s
integrated Ambulnz medical transport services, DocGo is bridging
the gap between physical and virtual care. For more information,
please visit www.docgo.com. To get an inside look on how the
proactive healthcare revolution is helping transform healthcare by
reducing costs, increasing efficiency and improving outcomes, visit
www.proactivecarenow.com.
Forward-Looking Statements
This earnings release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, regarding, among other things, the plans, strategies,
outcomes, and prospects, both business and financial, of the
Company, including the Company’s expectations around the
performance of each of its verticals; the impact of government
policy changes; the Company’s profitability and efforts to reduce
SG&A as a percentage of revenues; cash flow and cash
collections; the Company’s cash balances; and the Company’s future
growth and M&A activity. These statements are based on the
beliefs and assumptions of the Company’s management. Although the
Company believes that its plans, intentions and expectations
reflected in or suggested by these forward-looking statements are
reasonable, the Company cannot assure you that it will achieve or
realize these plans, intentions, outcomes, results or expectations.
Accordingly, you should not place undue reliance on such
statements. All statements other than statements of historical fact
are forward-looking, including, but not limited, to statements
regarding the Company’s future actions, business strategies or
models, plans, goals, future events, future revenues, future
margins, current and future revenue guidance, future growth or
performance, financing needs, business trends, results of
operations, objectives and intentions with respect to future
operations, services and products, and new and existing contracts
or partnerships. In some cases, these statements may be preceded
by, followed by or include the words “believes,” “estimates,”
“expects,” “projects,” “forecasts,” “may,” “might,” “will,”
“should,” “could,” “can,” “would,” “design,” “potential,” “seeks,”
“plans,” “scheduled,” “anticipates,” “intends” or the negative of
these terms or similar expressions.
Forward-looking statements are inherently subject to substantial
risks, uncertainties and assumptions, many of which are beyond the
Company’s control, and which may cause its actual results or
outcomes, or the timing of its results or outcomes, to differ
materially from those contained in its forward-looking statements,
including, but not limited to the following: impacts related to
accelerated wind down of migrant-related services; uncertainties
related to future non-migrant municipal population health revenue;
the Company’s ability to return to profitability and/or expand its
programs with insurance partners, hospital systems, municipalities
and other strategic partners; the Company’s ability to successfully
implement its business strategy, including delivering value to
shareholders via buybacks, funding new strategic relationships and
potentially repaying its line of credit; the Company’s ability to
establish, maintain and grow customer relationships; the Company’s
ability to execute projects to the satisfaction of its customers;
the Company’s ability to grow demand for its care gap closure
programs; the Company’s ability to maintain or grow its cash
balances; the Company’s reliance on and ability to maintain its
contractual relationships with its healthcare provider partners and
other strategic partners; the Company’s ability to compete
effectively in a highly competitive industry, including conditions
in the healthcare transportation and mobile health services
markets; the Company’s ability to maintain existing contracts; the
Company’s reliance on government contracts, including changes in
government spending on healthcare and other social services; recent
revenue growth derived from a small number of large customers; the
Company’s ability to effectively manage its growth; the Company’s
financial performance and future prospects; the Company’s ability
to deliver on its business strategies or models, plans and goals;
the Company’s ability to expand geographically; the Company’s
M&A activity and success of its acquisition strategy; the
Company’s ability to retain its workforce and management personnel
and successfully manage leadership transitions; the availability of
healthcare professionals and other personnel; changes in the cost
of labor; the Company’s ability to collect on customer receivables;
risks associated with the Company’s share repurchase program;
overall macroeconomic and geopolitical conditions, including the
interest rate environment, the inflationary environment, the
potential recessionary environment, regional conflict and tensions,
financial institution instability and the prospect of a shutdown of
the U.S. federal government; the ability of the Company’s suppliers
to meet its needs; the Company’s ability to obtain or maintain
operating licenses; potential changes in federal, state or local
government policies or priorities; expected impacts of geopolitical
instability; the Company’s competitive position and opportunities,
including its ability to realize the benefits from its operating
model; the Company’s ability to improve gross margins; the
Company’s ability to implement and deliver on cost-containment
measures and ongoing cost rationalization initiatives; legislative
and regulatory actions; the impact of legal proceedings and
compliance risk; volatility of our stock price; the impact on the
Company’s business and reputation in the event of information
technology system failures, network disruptions, cyber incidents or
losses or unauthorized access to, or release of, confidential
information; the Company’s ability to comply with laws and
regulations regarding data privacy and protection and other risk
factors included in the Company’s filings with the Securities and
Exchange Commission (“SEC”).
Moreover, the Company operates in a very competitive and rapidly
changing environment. New risks and uncertainties emerge from time
to time, and it is not possible for the Company to predict all
risks and uncertainties that could have an impact on the
forward-looking statements contained in this earnings release. The
results, events, and circumstances reflected in the forward-looking
statements may not be achieved or occur, and actual results or
outcomes could differ materially from those described in the
forward-looking statements.
The forward-looking statements made in this earnings release are
based on events or circumstances as of the date on which the
statements are made. The Company undertakes no obligation to update
any forward-looking statements made in this earnings release to
reflect events or circumstances after the date of this earnings
release or to reflect new information or the occurrence of
unanticipated events, except as and to the extent required by law.
The Company’s forward-looking statements do not reflect the
potential impact of any future acquisitions, mergers, dispositions,
joint ventures or investments.
DocGo Inc. and
Subsidiaries
UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS
March 31,2025 December 31,2024 Unaudited
Audited ASSETS Current assets: Cash and cash
equivalents
$
79,007,535
$
89,241,695
Accounts receivable, net of allowance for credit loss of $5,782,232
and $5,873,942 as of March 31, 2025 and December 31, 2024,
respectively
178,755,898
210,899,926
Prepaid expenses and other current assets
4,767,998
4,344,642
Total current assets
262,531,431
304,486,263
Property and equipment, net
15,049,767
14,881,411
Intangibles, net
27,343,578
25,728,813
Goodwill
49,554,226
47,432,550
Restricted cash
24,051,509
18,095,612
Operating lease right-of-use assets
13,665,630
11,958,698
Finance lease right-of-use assets
17,159,190
15,337,299
Investments
5,507,281
5,547,979
Deferred tax assets
12,349,462
8,422,034
Other assets
3,580,924
3,730,473
Total assets
$
430,792,998
$
455,621,132
LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities:
Accounts payable
$
20,518,829
$
28,356,430
Accrued liabilities
41,406,981
49,896,796
Line of credit
30,000,000
30,000,000
Notes payable, current
12,931
12,515
Due to seller
1,138,075
28,656
Contingent consideration
4,947,614
4,973,152
Operating lease liability, current
4,447,517
3,844,561
Finance lease liability, current
5,099,151
4,694,467
Total current liabilities
107,571,098
121,806,577
Notes payable, non-current
2,155
5,215
Operating lease liability, non-current
9,898,110
8,599,072
Finance lease liability, non-current
11,396,832
10,031,138
Total liabilities
128,868,195
140,442,002
Commitments and contingencies Stockholders’ equity: Common stock
($0.0001 par value; 500,000,000 shares authorized as of March 31,
2025 and December 31, 2024; 100,183,888 and 101,910,883 shares
issued and outstanding as of March 31, 2025 and December 31, 2024,
respectively)
10,018
10,191
Additional paid-in-capital
318,417,191
321,087,583
Accumulated deficit
(10,807,482
)
(1,402,167
)
Accumulated other comprehensive income
1,717,407
1,221,869
Total stockholders’ equity attributable to DocGo Inc. and
Subsidiaries
309,337,134
320,917,476
Noncontrolling interests
(7,412,331
)
(5,738,346
)
Total stockholders’ equity
301,924,803
315,179,130
Total liabilities and stockholders’ equity
$
430,792,998
$
455,621,132
DocGo Inc. and
Subsidiaries
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS)
INCOME
Three Months EndedMarch 31,
2025
2024
Revenues, net
$
96,033,055
$
192,087,529
Expenses: Cost of revenues (exclusive of depreciation and
amortization, which is shown separately below)
65,185,060
124,808,914
Operating expenses: General and administrative
32,902,070
40,181,035
Depreciation and amortization
3,761,391
4,182,781
Legal and regulatory
4,210,823
4,313,503
Technology and development
3,639,444
2,388,919
Sales, advertising and marketing
331,705
337,010
Total expenses
110,030,493
176,212,162
(Loss) income from operations
(13,997,438
)
15,875,367
Other expense: Interest (expense), net
(426,284
)
(369,008
)
Change in fair value of contingent liability
—
6,446
(Loss) on equity method investments
(40,698
)
(83,167
)
(Loss) on remeasurement of operating and finance leases
(40,837
)
(4,697
)
Gain on disposal of fixed assets
15,139
52,835
Other (expense) income
(312,869
)
244,607
Total other (expense)
(805,549
)
(152,984
)
Net (loss) income before income tax (expense) benefit
(14,802,987
)
15,722,383
Benefit from (provision for) income taxes
3,723,687
(5,119,004
)
Net (loss) income
(11,079,300
)
10,603,379
Net loss attributable to noncontrolling interests
(1,673,985
)
(624,070
)
Net (loss) income attributable to stockholders of DocGo Inc. and
Subsidiaries
(9,405,315
)
11,227,449
Other comprehensive income Foreign currency translation adjustment
495,538
(140,134
)
Total comprehensive (loss) income
$
(8,909,777
)
$
11,087,315
Net (loss) income per share attributable to DocGo Inc. and
Subsidiaries - Basic
$
(0.09
)
$
0.11
Weighted-average shares outstanding - Basic
101,594,579
103,818,362
Net (loss) income per share attributable to DocGo Inc. and
Subsidiaries - Diluted
$
(0.09
)
$
0.10
Weighted-average shares outstanding - Diluted
101,594,579
108,506,435
DocGo Inc. and
Subsidiaries
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months EndedMarch 31,
2025
2024
CASH FLOWS FROM OPERATING ACTIVITIES: Net (loss) income
$
(11,079,300
)
$
10,603,379
Adjustments to reconcile net (loss) income to net cash provided by
(used in) operating activities: Depreciation of property and
equipment
1,220,806
1,431,308
Amortization of intangible assets
1,299,142
1,694,983
Amortization of finance lease right-of-use assets
1,241,443
1,056,490
Gain on disposal of fixed assets
(15,139
)
(52,835
)
Deferred income tax
(3,927,428
)
(55,776
)
Loss on equity method investments
40,698
83,167
Bad debt expense
1,247,991
1,357,621
Stock-based compensation
4,830,312
3,988,339
Loss on remeasurement of operating and finance leases
40,837
4,697
Change in fair value of contingent consideration
—
(6,446
)
Changes in operating assets and liabilities: Accounts receivable
31,437,734
(22,401,596
)
Prepaid expenses and other current assets
(386,734
)
6,728,337
Other assets
538,190
(62,016
)
Accounts payable
(7,684,101
)
5,800,891
Accrued liabilities
(9,148,984
)
(20,810,287
)
Net cash provided by (used in) operating activities
9,655,467
(10,639,744
)
CASH FLOWS FROM INVESTING ACTIVITIES: Acquisition of
property and equipment
(1,468,364
)
(951,702
)
Acquisition of intangibles
(712,711
)
(773,039
)
Acquisition of a business
(3,646,318
)
—
Proceeds from disposal of property and equipment
94,341
25,000
Net cash used in investing activities
(5,733,052
)
(1,699,741
)
CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from
revolving credit line
—
45,000,000
Repayments of revolving credit line
—
(40,000,000
)
Repayments of notes payable
(3,060
)
(9,624
)
Due to seller
—
(3,862
)
Earnout payments on contingent liabilities
(265,538
)
—
Payments for taxes related to shares withheld for employee taxes
(1,200,977
)
(20,946
)
Common stock repurchased
(5,751,954
)
(4,877,559
)
Payments on obligations under finance lease
(1,296,887
)
(969,588
)
Net cash used in financing activities
(8,518,416
)
(881,579
)
Effect of exchange rate changes on cash and cash equivalents
317,738
(103,059
)
Net decrease in cash and restricted cash
(4,278,263
)
(13,324,123
)
Cash and restricted cash at beginning of period
107,337,307
72,217,986
Cash and restricted cash at end of period
$
103,059,044
$
58,893,863
Three Months EndedMarch 31,
2025
2024
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest
$
561,707
$
448,057
Cash paid for interest on finance lease liabilities
$
220,055
$
181,883
Cash paid for income taxes
$
1,906,712
$
557,598
Right-of-use assets obtained in exchange for lease liabilities
$
5,966,095
$
2,791,964
Remeasurement of finance lease right-of-use asset due to lease
modification
$
—
$
300,000
Reconciliation of cash and restricted cash Cash
$
79,007,535
$
41,244,446
Restricted cash
24,051,509
17,649,417
Total cash and restricted cash shown in statement of cash flows
$
103,059,044
$
58,893,863
Non-GAAP Financial Measures
The following information provides definitions and
reconciliation of non-GAAP financial measures used by the Company
to the most directly comparable financial measures calculated and
presented in accordance with generally accepted accounting
principles (“GAAP”). The Company has provided this non-GAAP
financial information, which is not calculated or presented in
accordance with GAAP, as information supplemental and in addition
to the financial measures presented in this earnings release that
are calculated and presented in accordance with GAAP. Such non-GAAP
financial measures should not be considered superior to, as a
substitute for or alternative to, and should be considered in
conjunction with, the GAAP financial measures presented in this
earnings release. The non-GAAP financial measures used by the
Company may differ from similarly titled measures used by other
companies.
Adjusted Gross Margin
Adjusted gross profit and adjusted gross margin are considered
non-GAAP financial measures under SEC rules because they exclude
certain amounts included in gross profit and gross margin
calculated in accordance with GAAP. Adjusted gross profit is total
revenue minus cost of revenue, excluding depreciation and
amortization (which are shown separately), and adjusted gross
margin is adjusted gross profit as a percentage of total
revenue.
The Company’s management believes that adjusted gross margin is
useful in evaluating DocGo’s operating performance, as the
calculation of this measure excludes the impact of non-cash
depreciation and amortization charges. The Company’s management
believes that by using adjusted gross margin in conjunction with
GAAP gross margin, investors will get a more complete view of what
management considers to be the Company’s core operating performance
and allow for comparison of this measure when compared to those of
prior periods. While many companies use adjusted gross margin as a
performance measure, not all companies use identical calculations
for determining adjusted gross margin. As such, DocGo’s
presentation of adjusted gross margin might not be comparable to
similarly titled measures of other companies.
Adjusted EBITDA
Adjusted EBITDA is considered a non-GAAP financial measure under
SEC rules because it excludes certain amounts included in net
income (loss) calculated in accordance with GAAP. Specifically,
adjusted EBITDA is arrived at by taking reported GAAP net income
and adding back the following items: net interest expense (income),
provision for (benefit from) income taxes, depreciation and
amortization, other (income) expense, non-cash equity-based
compensation and certain other non-recurring expenses consisting of
certain one-time legal settlements and certain one-time expenses
incurred in connection with acquisitions and other corporate
activities, beyond those that are typically incurred.
The Company’s management believes that its adjusted EBITDA
measure is useful in evaluating DocGo’s operating performance, as
the calculation of this measure generally eliminates the effect of
financing and income taxes and the accounting effects of capital
spending and acquisitions, as well as other items of a
non-recurring and/or non-cash nature. Adjusted EBITDA is not
intended to be a measure of GAAP cash flow, as this measure does
not consider certain cash-based expenses, such as payments for
taxes or debt service.
Management believes that using adjusted EBITDA in conjunction
with GAAP measures such as net income assists investors in getting
a more complete picture of the Company’s financial results and
operations, affording them with a more complete view of what
management considers to be the Company’s core operating performance
as well as offering the ability to assess such performance as
compared with that of prior periods and management’s public
guidance. While many companies use adjusted EBITDA as a performance
measure, not all companies use identical calculations for
determining adjusted EBITDA. As such, DocGo’s presentation of
adjusted EBITDA might not be comparable to similarly titled
measures of other companies.
Adjusted EBITDA Margin
Adjusted EBITDA margin is considered a non-GAAP measure under
SEC rules. It is calculated by dividing adjusted EBITDA by
revenues. Management believes using adjusted EBITDA margin in
conjunction with GAAP measures, such as gross margin and/or net
margin, is useful to investors because it assists investors in
getting a more complete view of what management considers the
Company’s core operating performance, as expressed in marginal
terms. While many companies use adjusted EBITDA margin as a
performance measure, not all companies use identical calculations
for determining adjusted EBITDA margin. As such, DocGo’s
presentation of adjusted EBITDA margin might not be comparable to
similarly titled measures of other companies.
Reconciliation of Non-GAAP Measures
The table below reflects the reconciliation of GAAP gross margin
and adjusted gross margin for the three months ended March 31, 2025
compared to the same period in 2024:
Three Months EndedMarch 31,
2025
2024
Revenue
$96,033,055
$192,087,529
Cost of revenue (exclusive of depreciation and amortization, which
are shown separately below)
(65,185,060)
(124,808,914)
Depreciation and amortization
(3,761,391)
(4,182,781)
GAAP gross profit
27,086,604
63,095,834
Depreciation and amortization
3,761,391
4,182,781
Adjusted gross profit
30,847,995
67,278,615
GAAP gross margin
28.2%
32.8%
Adjusted gross margin
32.1%
35.0%
The table below reflects the reconciliation of net income (loss)
to adjusted EBITDA for the three months ended March 31, 2025
compared to the same period in 2024 (in millions):
Three Months EndedMarch 31,
2025
2024
Net income (GAAP)
($11.1)
$10.6
(+) Net interest expense
$0.4
$0.4
(+) Income tax
($3.7)
$5.1
(+) Depreciation and amortization
$3.8
$4.2
(+) Other (income) expense
$0.4
($0.2)
EBITDA
($10.2)
$20.1
(+) Non-cash stock compensation
$4.8
$4.0
(+) Non-recurring expense
$1.5
$0.0
Adjusted EBITDA
($3.9)
$24.1
Total revenue
$96.0
$192.1
Pretax income margin
-15.4%
8.2%
Net margin
-11.6%
5.5%
Adjusted EBITDA margin
-4.1%
12.5%
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250508310873/en/
Investors: Mike Cole DocGo 949-444-1341
mike.cole@docgo.com ir@docgo.com
DocGo (NASDAQ:DCGO)
Historical Stock Chart
From Jun 2025 to Jul 2025
DocGo (NASDAQ:DCGO)
Historical Stock Chart
From Jul 2024 to Jul 2025
